Department of Pathology, Boston University School of Medicine, Boston, Massachusetts, USA.
Physiol Rev. 2013 Jul;93(3):1247-88. doi: 10.1152/physrev.00037.2012.
Sepsis represents the host's systemic inflammatory response to a severe infection. It causes substantial human morbidity resulting in hundreds of thousands of deaths each year. Despite decades of intense research, the basic mechanisms still remain elusive. In either experimental animal models of sepsis or human patients, there are substantial physiological changes, many of which may result in subsequent organ injury. Variations in age, gender, and medical comorbidities including diabetes and renal failure create additional complexity that influence the outcomes in septic patients. Specific system-based alterations, such as the coagulopathy observed in sepsis, offer both potential insight and possible therapeutic targets. Intracellular stress induces changes in the endoplasmic reticulum yielding misfolded proteins that contribute to the underlying pathophysiological changes. With these multiple changes it is difficult to precisely classify an individual's response in sepsis as proinflammatory or immunosuppressed. This heterogeneity also may explain why most therapeutic interventions have not improved survival. Given the complexity of sepsis, biomarkers and mathematical models offer potential guidance once they have been carefully validated. This review discusses each of these important factors to provide a framework for understanding the complex and current challenges of managing the septic patient. Clinical trial failures and the therapeutic interventions that have proven successful are also discussed.
败血症代表宿主对严重感染的全身炎症反应。它导致大量的人类发病率,导致每年数十万人死亡。尽管经过数十年的深入研究,基本机制仍然难以捉摸。在败血症的实验动物模型或人类患者中,存在大量的生理变化,其中许多可能导致随后的器官损伤。年龄、性别和医疗合并症(包括糖尿病和肾衰竭)的差异增加了复杂性,影响了败血症患者的结局。特定的基于系统的改变,如败血症中观察到的凝血功能障碍,提供了潜在的见解和可能的治疗靶点。细胞内应激导致内质网的变化,产生错误折叠的蛋白质,导致潜在的病理生理变化。由于这些多种变化,很难准确地将个体对败血症的反应分类为促炎或免疫抑制。这种异质性也可能解释为什么大多数治疗干预措施并未改善存活率。鉴于败血症的复杂性,生物标志物和数学模型提供了潜在的指导,一旦经过仔细验证。这篇综述讨论了这些重要因素中的每一个,以提供一个框架来理解管理败血症患者的复杂和当前挑战。还讨论了临床试验失败和已被证明成功的治疗干预措施。